Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07733947
PHASE3

A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1)

Sponsor: Caliway Biopharmaceuticals Co., Ltd.

View on ClinicalTrials.gov

Summary

A Phase 3b, Multicenter, Two stage, Double-blind, Long term Follow up and Open-label Extension Study of Participants Who have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)

Official title: A Phase 3b, Multicenter, Two Stage, Double-blind, Long Term Follow up and Open Label Extension Study of Participants Who Have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2026-12

Completion Date

2028-09

Last Updated

2026-10-19

Healthy Volunteers

No

Interventions

DRUG

CBL-514 Injection

Provided as a ready for use injectable CBL-514 solution

DRUG

0.9 % sodium chloride

Injectable 0.9% Sodium Chloride solution as placebo

Locations (1)

Investigational site 1

Encinitas, California, United States